Entrepreneur
Career, family and the motherhood penalty that lies ahead
As UK childcare costs account for 26 per cent of household income, fintech entrepreneur Mel Faxon explains why motherhood means that women can’t have it all.
Mel joins me from her London coworking space. “Being able to walk over to someone’s desk, especially when you’re in a start-up, makes such a huge difference. I can’t wait until we have an office” she candidly admits.
Faxon met Siran Cao, her now co-founder, in 2019. As two millennial women, they started looking at why we often refuse to think about our bodies and careers on the same track. A few coffee conversations later, they decided to make a change in the way we perceive the idea of starting a family and they created Mirza, a care now pay later product that aims to distribute the costs of childcare over time and close the gender pay gap.
“When we first started, we were looking at the causes of the motherhood penalty and the decline in earnings that a woman sees after she has a child,” Faxon says. “This is one of the biggest contributors to the gender pay gap and if you don’t have good parental or maternity leave, it can hurt your career acceleration down the line.”
Taking time out of the workforce after stepping into motherhood is something that women naturally do, mainly because they can’t afford the increasing costs of childcare. However, the long-term financial implications are a lot bigger than we might think, the entrepreneur adds.
“We wanted to tackle this issue by launching a product that helps women keep working and that distributes the [childcare] costs over time to when they have higher earning potential,” she explains. “We want to allow women to take this zero-interest financing mechanism through their employer without having to choose between family and career.”
Mirza was initially aimed for women, but the two co-founders soon realised parenthood shouldn’t be one-sided. “We wanted a family-focused financial planning product that helps parents understand what the parenthood penalty looks like and what taking unpaid leave looks like,” Faxon says.
“Once we realised that this is not just about women, we decided to shift [our idea] and make it much more gender neutral for both men and women.
“We constantly hear things like ‘I don’t want to have to choose between family and career’ or ‘women can have it all’. But right now, it’s unrealistic to think that women can have it all unless they have a lot of privilege and support.”
With one in three childcare centres shutting down in the US and over two million women dropping out of work during the pandemic, the need for a change seemed even more imperative.
“Covid has been a really good spotlight,” the co-founder adds. “This great resignation really highlights that people aren’t going to go back to work in places where they don’t get the support that they need and it also shows that care is the future of work. If we don’t support parents in their childcare needs, they are not going to be able to participate in the economy and help it grow.”
But why is financial planning so important in this process?
“Everything gets so disorganised when you have a child,” Faxon explains. “You don’t know where to go and you feel like you don’t have a balance between your career, what you were doing in the past and your current life.
“Financial planning helps people be a little bit more proactive. Having a child, then looking for childcare and realising what the expense is going to be, is very much a reactive approach that can mean that one of the parents would have to stay home.
“We want to help parents start these conversations ahead of time to help facilitate that dialogue around parental leave policies and statutory leaving,” she continues. “That would give them a sense of control and would help them navigate that with their employer.”
Mirza is purely tech-driven and is able to source some of the expenses that are coming up and taking your income into account, it will estimate the upcoming cost of care for the coming five to ten years. It is already available in the US, mainly because the data used was based on a US model.
“Both my co-founder and I are American. So, it felt a little bit more genuine for us to tackle those problems there,” Faxon says. “But our whole team is here, in London and we would love to expand it to the UK in a few years.”
Mirza’s five-year goal is to shape parental leave and have over two million families using the service. “Our vision is to become almost like a neobank of offering more tailored financial products for families ,” the co-founder adds.
“Women shouldn’t have to take that financial hit right when they have their first child and I hope we will change that.”
To find more about Mirza visit heymirza.com.
Entrepreneur
Kate Ryder headlines Women’s Health Week USA 2026 as full agenda goes live
Women’s Health Week USA 2026 has unveiled its first populated agenda, anchored by an opening keynote from Kate Ryder, Founder and CEO of Maven Clinic, and featuring a cross-sector lineup shaping the next phase of scale in women’s health.
You can view the full agenda here.
Taking place May 13–14, 2026, at the New York Academy of Medicine, Women’s Health Week USA brings together the full women’s health ecosystem to focus on one central question: what does it take to move women’s health from innovation to institutional scale?
Kate Ryder will open Day 1 with a keynote drawing on her experience building Maven Clinic into the world’s largest virtual clinic for women’s and family health.
Under her leadership, Maven has partnered with employers and health plans to deliver care across fertility, maternity, postpartum, paediatrics, and menopause at scale.
Her perspective sets the tone for a program centered on commercialisation, partnership, and sustainable growth.
Beyond the opening keynote, the newly released agenda reflects the sector’s growing maturity.
Across two days, the program features 70+ speakers, with representation from leading organizations including the FDA, Planned Parenthood, CVS Health Ventures, Samsung Next, NIH, WHO, and Maven Clinic.
Sessions span investment and deal flow, clinical innovation, regulation, data and technology, and market expansion, alongside dedicated pitch sessions and curated 1:1 matchmaking designed to turn insight into action.
The agenda has been built to facilitate meaningful connections across the ecosystem, with partnerships positioned as the primary driver of scale.
As women’s health continues to attract institutional capital and global attention, Women’s Health Week USA 2026 offers a clear snapshot of where the market is heading, and who is shaping it.
The full agenda is now live, with additional speakers and partners to be announced in the coming months.
View the full programme here.
Entrepreneur
Merck partners on intravaginal drug delivery device
Calla Lily Clinical Care has partnered with Merck to support the intravaginal drug delivery platform Callavid in an effort to improve how vaginal medicines are given.
The collaboration will continue development of Callavid, described as a leak-resistant device that addresses challenges with self-administered vaginal therapies.
Callavid uses a small, tampon-shaped device with an integrated absorbent liner. It is inserted, remains in place during drug absorption, then is removed.
The platform is intended for use with medicines in fertility treatment, oncology and hormone therapy. Administration via the vaginal route can prompt patient anxiety about positioning, dosing accuracy and leakage.
The partnership is the first industry collaboration for the Callavid technology, which was developed by Calla Lily Clinical Care.
Thang Vo-Ta, co-founder and chief executive of Calla Lily Clinical Care, said: “This collaboration with Merck marks an important milestone in the development of Callavid, our novel vaginal drug delivery platform.
“Merck’s scientific heritage and forward-looking approach to innovation make them an ideal partner as we work to address long-standing unmet needs in women’s health.
“By improving how vaginal therapeutics are delivered and experienced, Callavid has the potential to enhance both patient outcomes and quality of life.
“We see this collaboration as a meaningful step towards translating our technology into real-world clinical and patient impact.”
Calla Lily Clinical Care is seeking to develop what it describes as the world’s first drug-device combination product to prevent threatened miscarriage and for IVF luteal phase support, the phase after ovulation when the body produces progesterone to support early pregnancy.
The device is also being developed to deliver therapeutics for oncology, menopause, infectious diseases and live biotherapeutics to reduce repeated antibiotic use.
Dr Lara Zibners, co-founder and chairman of Calla Lily Clinical Care, said: “Our initial engagement with Merck through the Merck Innovation Challenge in October 2024 was an important moment of alignment around the need for more patient-centric innovation in women’s health.
“As both a clinician and a patient, I have seen how profoundly drug delivery can shape treatment experience.
“This collaboration builds on that early dialogue and reflects a shared interest in rigorously exploring new approaches that may improve how therapies are delivered and experienced by patients.”
Entrepreneur
US startup builds wearable hormone tracker
-
Features4 weeks agoWomen’s health enters a new era – the trends shaping femtech in 2026
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Features4 weeks agoBest menopause apps and products for 2026
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoHigher maternal blood pressure increases risk of pregnancy complications, study finds
-
Entrepreneur4 weeks agoXella Health closes US$3.7 million in pre-seed financing
-
Insight3 weeks agoChina’s birth rate hits record low despite government fertility efforts







2 Comments